@article{ea9fdd9ce2984847a9be544747d3dbf4,
title = "Cardiovascular safety of febuxostat - Authors' reply",
author = "MacDonald, {Thomas M.} and George Nuki and Michele Robertson and Ian Ford and Mackenzie, {Isla S.}",
note = "Funding -TMM reports grants from Novartis, Pfizer, GlaxoSmithKline, Amgen, and Menarini, unrelated to this Correspondence, and consultancy or speaker fees from Novartis, Takeda, Servier, Shire, Astellus, Menarini, and AstraZeneca. GN, MR, and IF report grants from Menarini via the University of Dundee, unrelated to this Correspondence. ISM reports research grants from Novartis, the National Institute for Health Research Health Technology Assessment programme, Amgen, Research Triangle Institute, Tenovus Scotland, George Clinical, European Medicines Agency, Sanofi, Health Data Research UK, Innovative Medicines Initiative, and Menarini, and personal income from AstraZeneca, unrelated to this Correspondence.",
year = "2021",
month = sep,
day = "11",
doi = "10.1016/S0140-6736(21)01383-0",
language = "English",
volume = "398",
pages = "955--956",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier",
number = "10304",
}